Login Register Cart 0
Generic placeholder image

Coronaviruses

Editor-in-Chief

ISSN (Print): 2666-7967
ISSN (Online): 2666-7975

Back
Journal Home About Journal Editorial Board Current Issue Volumes/Issues
Subscribe
Review Article

Therapeutic Options for the Treatment of 2019-Novel Coronavirus in India: A Review

Author(s): Pratyay Kumar Pahari, Sonal Vyas, Shahbaz Aman, Uday Singh, Kusheswar Prasad Singh, Rohit Tiwari and Meenakshi Dhanawat*

Volume 3, Issue 2, 2022

Published on: 04 December, 2020

Article ID: e041220188720 Pages: 9

DOI: 10.2174/2666796701999201204115545

Price: $65

Abstract

Purpose: As of, from 30th Jan to 31st May, 2020, more than 182,143 confirmed cases were reported in India along with 86,984 recovered cases and 5164 deceased cases of COVID-19. More than 53 countries are also affected with this pandemic virus. However, the lack of specific drugs to prevent/treat this pandemic disease is a major problem in this current scenario. In this regard, this systemic review was conducted to identify the therapeutic approaches and researches, which are ongoing in India against COVID-19.

Methods: We had screened Google Scholar database with the keywords nCoV, corona virus in India, effect of SARS-CoV-2 in India, 2019-nCoV, treatment pattern in India for nCoV and therapy used to treat nCoV in India. In the final review, we had included a total of 49 articles.

Results: As a result we had found that the Indian Council of Medical Research and NIH have given a standard guideline of Hydroxychloroquine and other antiviral drugs for nCoV, and also there are various researches going on related to nCoV treatment like, chemicals from natural products, herbs and spices commonly used in India, combination therapy of lopinavir and ritonavir, ultra-violet radiation therapy, molecular dynamic (MD) simulations of molecules for vaccine preparation, Convalescent plasma transfusion (CPT) therapy and many more.

Conclusions: New drugs and therapy are in the premature stage for this hazardous pandemic. We need more time to gain the detailed knowledge of the life cycle of the nCoV, which can speed up the drug/vaccine development process against nCoV.

Keywords: Novel coronavirus, nCoV, treatment of nCoV, SARS-CoV-2, ICMR, NIH.

[1]
Chatterjee K, Chatterjee K, Kumar A, Shankar S. Healthcare impact of COVID-19 epidemic in India: A stochastic mathematical model. Med J Armed Forces India 2020; 76(2): 147-55.
[http://dx.doi.org/10.1016/j.mjafi.2020.03.022] [PMID: 32292232]
[2]
Kaushik S, Kaushik S, Sharma Y, Kumar R, Yadav JP. The Indian perspective of COVID-19 outbreak. Virusdisease 2020; 1-8.
[http://dx.doi.org/10.1007/s13337-020-00587-x] [PMID: 32368570]
[3]
Chatterjee P, Nagi N, Agarwal A, et al. The 2019 novel coronavirus disease (COVID-19) pandemic: A review of the current evidence. Indian J Med Res 2020; 151(2 & 3): 147-59.
[http://dx.doi.org/10.4103/ijmr.IJMR_519_20] [PMID: 32362642]
[4]
Prajapat M, Sarma P, Shekhar N, et al. Drug targets for corona virus: A systematic review. Indian J Pharmacol 2020; 52(1): 56-65.
[http://dx.doi.org/10.4103/ijp.IJP_115_20] [PMID: 32201449]
[5]
Malik YS, Sircar S, Bhat S, et al. Emerging novel coronavirus (2019-nCoV)-current scenario, evolutionary perspective based on genome analysis and recent developments. Vet Q 2020; 40(1): 68-76.
[http://dx.doi.org/10.1080/01652176.2020.1727993] [PMID: 32036774]
[6]
McIntosh K, Perlman S. Coronaviruses, Including Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS)Mand Douglas, Bennett’s Princ Pract Infect Dis. 2014.
[7]
Li W, Moore MJ, Vasilieva N, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 2003; 426(6965): 450-4.
[http://dx.doi.org/10.1038/nature02145] [PMID: 14647384]
[8]
Mubarak A, Alturaiki W, Hemida MG. Middle East Respiratory Syndrome Coronavirus (MERS-CoV): Infection, Immunological Response, and Vaccine Development. J Immunol Res 2019; 2019: 6491738.
[http://dx.doi.org/10.1155/2019/6491738] [PMID: 31089478]
[9]
te Velthuis AJW, van den Worm SHE, Snijder EJ. The SARS- coronavirus nsp7+nsp8 complex is a unique multimeric RNA polymerase capable of both de novo initiation and primer extension. Nucleic Acids Res 2012; 40(4): 1737-47.
[http://dx.doi.org/10.1093/nar/gkr893] [PMID: 22039154]
[10]
Wang H, Xue S, Yang H, Chen C. Recent progress in the discovery of inhibitors targeting coronavirus proteases. Virol Sin 2016; 31(1): 24-30.
[http://dx.doi.org/10.1007/s12250-015-3711-3] [PMID: 26920707]
[11]
Narayanan K, Maeda A, Maeda J, Makino S. Characterization of the coronavirus M protein and nucleocapsid interaction in infected cells. J Virol 2000; 74(17): 8127-34.
[http://dx.doi.org/10.1128/JVI.74.17.8127-8134.2000] [PMID: 10933723]
[12]
de Wit E, van Doremalen N, Falzarano D, Munster VJ. SARS and MERS: recent insights into emerging coronaviruses. Nat Rev Microbiol 2016; 14(8): 523-34.
[http://dx.doi.org/10.1038/nrmicro.2016.81] [PMID: 27344959]
[13]
Nieto-Torres JL, Dediego ML, Álvarez E, et al. Subcellular location and topology of severe acute respiratory syndrome coronavirus envelope protein. Virology 2011; 415(2): 69-82.
[http://dx.doi.org/10.1016/j.virol.2011.03.029] [PMID: 21524776]
[14]
Ding Y, He L, Zhang Q, et al. Organ distribution of severe acute respiratory syndrome (SARS) associated coronavirus (SARS- CoV) in SARS patients: implications for pathogenesis and virus transmission pathways. J Pathol 2004; 203(2): 622-30.
[http://dx.doi.org/10.1002/path.1560] [PMID: 15141376]
[15]
Agrawal S, Goel AD, Gupta N. Emerging prophylaxis strategies against COVID-19. Monaldi Arch Chest Dis 2020; 90(1): 169-72.
[http://dx.doi.org/10.4081/monaldi.2020.1289] [PMID: 32231348]
[16]
indian council of medical research, AdvisoryontheuseofHydroxychloroquinasprophylaxisforSARSCoV2infectionpdf, govt of india, new delhi 2020.https://www.mohfw.gov.in/pdf/Advisoryontheuseof
[17]
Https://clinicaltrials.gov, Https://ClinicalTrials.gov2019.
[18]
Behind R, Use C. Batra U, Sharma M, Redhu P. Chloroquine and hydroxychloroquine: Clutching at straws in the time of COVID-19? 2020; 3(5): 3-6.
[19]
Sarma P, Kaur H, Kumar H, et al. Virological and clinical cure in COVID-19 patients treated with hydroxychloroquine: A systematic review and meta-analysis. J Med Virol 2020; 92(7): 776-85.
[http://dx.doi.org/10.1002/jmv.25898] [PMID: 32297988]
[20]
Badyal DK, Mahajan R. Chloroquine: Can it be a Novel Drug for COVID-19. Int J Appl Basic Med Res 2020; 10(2): 128-30.
[http://dx.doi.org/10.4103/ijabmr.IJABMR_141_20] [PMID: 32363157]
[21]
Shah S, Das S, Jain A, Misra DP, Negi VS. A systematic review of the prophylactic role of chloroquine and hydroxychloroquine in coronavirus disease-19 (COVID-19). Int J Rheum Dis 2020; 23(5): 613-9.
[http://dx.doi.org/10.1111/1756-185X.13842] [PMID: 32281213]
[22]
Gupta N, Agrawal S, Ish P. Chloroquine in COVID-19: the evidence. Monaldi Arch Chest Dis 2020; 90(1): 177-9.
[http://dx.doi.org/10.4081/monaldi.2020.1290] [PMID: 32231349]
[23]
Kapoor KM, Kapoor A. Role of Chloroquine and Hydroxychloroquine in the Treatment of COVID-19 Infection- A Systematic Literature Review MedRxiv 2020.
[24]
Singh AK, Singh A, Shaikh A, Singh R, Misra A. Chloroquine and hydroxychloroquine in the treatment of COVID-19 with or without diabetes: A systematic search and a narrative review with a special reference to India and other developing countries. Diabetes Metab Syndr 2020; 14(3): 241-6.
[http://dx.doi.org/10.1016/j.dsx.2020.03.011] [PMID: 32247211]
[25]
Shetty R, Ghosh A, Honavar SG, Khamar P, Sethu S. Therapeutic opportunities to manage COVID-19/SARS-CoV-2 infection: Present and future. Indian J Ophthalmol 2020; 68(5): 693-702.
[http://dx.doi.org/10.4103/ijo.IJO_639_20] [PMID: 32317431]
[26]
Sarma P, Prajapat M, Avti P, Kaur H, Kumar S, Medhi B. Therapeutic options for the treatment of 2019-novel coronavirus: An evidence-based approach. Indian J Pharmacol 2020; 52(1): 1-5.
[http://dx.doi.org/10.4103/ijp.IJP_119_20] [PMID: 32201439]
[27]
NIH, COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health, Nih 2020.https://www.covid19treatmentguidelines.nih.gov/
[28]
Tilangi P, Desai D, Khan A, Soneja M. Hydroxychloroquine prophylaxis for high-risk COVID-19 contacts in India: a prudent approach. Lancet Infect Dis 2020; 20(10): 1119-20.
[http://dx.doi.org/10.1016/S1473-3099(20)30430-8] [PMID: 32450054]
[29]
NIH: National Institute of Allergy and Infectious Diseases | Leading research to understand, treat, and prevent infectious, immunologic, and allergic diseases https://www.niaid.nih.gov/
[30]
Umesh U, Kundu D, Selvaraj C, Singh SK, Dubey VK. Identification of new anti-nCoV drug chemical compounds from Indian spices exploiting SARS-CoV-2 main protease as target. J Biomol Struct Dyn 2021; 39(9): 3428-34.
[http://dx.doi.org/10.1080/07391102.2020.1763202] [PMID: 32362243]
[31]
Khan RJ, Jha RK, Amera GM, et al. Targeting SARS-CoV-2: a systematic drug repurposing approach to identify promising inhibitors against 3C-like proteinase and 2′-O-ribose methyltransferase. J Biomol Struct Dyn 2021; 39(8): 2679-92.
[http://dx.doi.org/10.1080/07391102.2020.1753577] [PMID: 32266873]
[32]
Mittal L, Kumari A, Srivastava M, Singh M, Asthana S. Identification of potential molecules against COVID-19 main protease through structure-guided virtual screening approach. J Biomol Struct Dyn 2021; 39(10): 3662-80.
[http://dx.doi.org/10.1080/07391102.2020.1768151] [PMID: 32396769]
[33]
Ranjan A, Chauhan A, Gurnani M, Jindal, T. Potential Phytochemicals as Efficient Protease Inhibitors of 2019-nCoV. Preprints 2020, 2020040240
[http://dx.doi.org/10.20944/preprints202004.0240.v1]
[34]
Kim DW, Seo KH, Curtis-Long MJ, et al. Phenolic phytochemical displaying SARS-CoV papain-like protease inhibition from the seeds of Psoralea corylifolia. J Enzyme Inhib Med Chem 2014; 29(1): 59-63.
[http://dx.doi.org/10.3109/14756366.2012.753591] [PMID: 23323951]
[35]
Yang ZF, Bai LP, Huang WB, et al. Comparison of in vitro antiviral activity of tea polyphenols against influenza A and B viruses and structure-activity relationship analysis. Fitoterapia 2014; 93: 47-53.
[http://dx.doi.org/10.1016/j.fitote.2013.12.011] [PMID: 24370660]
[36]
Zhang T, Chen D. Anticomplementary principles of a Chinese multiherb remedy for the treatment and prevention of SARS. J Ethnopharmacol 2008; 117(2): 351-61.
[http://dx.doi.org/10.1016/j.jep.2008.02.012] [PMID: 18400428]
[37]
Chhikara BS, Rathi B, Singh J. Poonam, Corona virus SARS-CoV-2 disease COVID-19: Infection, prevention and clinical advances of the prospective chemical drug therapeutics. Chem Biol Lett 2020; 7: 63-72.
[38]
Muralidharan N, Sakthivel R, Velmurugan D, Gromiha MM. Computational studies of drug repurposing and synergism of lopinavir, oseltamivir and ritonavir binding with SARS-CoV-2 protease against COVID-19. J Biomol Struct Dyn 2020; 1-6.
[http://dx.doi.org/10.1080/07391102.2020.1752802] [PMID: 32248766]
[39]
Bhatnagar T, Murhekar MV, Soneja M, et al. Lopinavir/ritonavir combination therapy amongst symptomatic coronavirus disease 2019 patients in India: Protocol for restricted public health emergency use. Indian J Med Res 2020; 151(2 & 3): 184-9.
[http://dx.doi.org/10.4103/ijmr.IJMR_502_20] [PMID: 32362644]
[40]
Joshi RS, Jagdale SS, Bansode SB, et al. Discovery of potential multi-target-directed ligands by targeting host-specific SARS- CoV-2 structurally conserved main protease. J Biomol Struct Dyn 2020; 1-16.
[http://dx.doi.org/10.1080/07391102.2020.1760137] [PMID: 32329408]
[41]
Anandan R, Suseendran G, Zaman N, Brohi SN, Deepak BS. Echinacea purpurea to treat Novel Coronavirus ( 2019-nCoV ) 2019.
[42]
Baruah V, Bose S. Immunoinformatics-aided identification of T cell and B cell epitopes in the surface glycoprotein of 2019-nCoV. J Med Virol 2020; 92(5): 495-500.
[http://dx.doi.org/10.1002/jmv.25698] [PMID: 32022276]
[43]
Rajendran K, Krishnasamy N, Rangarajan J, Rathinam J, Natarajan M, Ramachandran A. Convalescent plasma transfusion for the treatment of COVID-19: Systematic review. J Med Virol 2020.
[44]
Teixeira da Silva JA. Convalescent plasma: A possible treatment of COVID-19 in India. Med J Armed Forces India 2020; 76(2): 236-7.
[http://dx.doi.org/10.1016/j.mjafi.2020.04.006] [PMID: 32296259]
[45]
Venkatraman P, Sahay JJ, Maidili T, Rajan R, Pooja S. Breakthrough of COVID-19 using radiotherapy treatment modalities. Radiother Oncol 2020; 148: 225-6.
[http://dx.doi.org/10.1016/j.radonc.2020.04.024] [PMID: 32342867]

Rights & Permissions Print Cite
Article Metrics
17
2
© 2024 Bentham Science Publishers | Privacy Policy